Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

Air NZ to airports: Stop subsidising Jetstar
Markets

Air NZ to airports: Stop subsidising Jetstar

Current airport regulation works against the national interest, Air NZ’s new CEO says.

Genesis sets out gas strategy
Markets

Genesis sets out gas strategy

Storage, Kupe’s long-term role and LNG flexibility anchor the plan.

Ports owned by councils ‘underperform’: time to list?
Markets

Ports owned by councils ‘underperform’: time to list?

There is clear evidence that listing leads to better businesses, market experts say.

RBNZ data scotches Dosh claims of bank registration application
Finance

RBNZ data scotches Dosh claims of bank registration application

The regulator received no bank-registration applications in July 2024.